medcelerator · clinician one-pager

First EU Medicine for Early Brain ALD in Boys Ages 2–12

Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)

EMA Authorised · European Union · September 25, 2026

Condition: Cerebral Adrenoleukodystrophy

Who this is for

This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on MRI and a Neurological Functional Score of 0 or 1 — and the caregivers helping them. It explains the European Commission marketing authorisation for Nezglyal (leriglitazone) oral suspension on 21 September 2026 under exceptional circumstances, how once-daily height- and weight-based dosing works from the SmPC, what NEXUS (MT-2-02) showed about arrested disease, and how to ask an ALD / leukodystrophy specialist about labelled EU supply versus HSCT timing — without claiming US or Canadian approval, treating open-label evidence as a cure, or importing an EU bottle. Authorized is not funded.

Next clinical step

This is authorised in the EU (EMA). Ask the clinician about EU labelling, availability in European Union, and whether a local pathway exists outside the EU.

Not medical advice. Authorized is not funded. Full piece: https://medcelerator.com/articles/nezglyal-leriglitazone-cald